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Published by Elsevier Inc.CORRESPONDENCELetters to the Editor
R
RAspirin Plus Clopidogrel
Versus Aspirin Alone After
Coronary Artery Bypass Grafting
We read with interest the paper by Gao et al. (1) relating to the use
of clopidogrel and aspirin after coronary artery bypass grafting
(CABG) surgery. As the authors point out, adding clopidogrel or
other P2Y12 receptor antagonists to aspirin may make antiplatelet
therapy more effective and may act as a safety net for CABG
patients with aspirin resistance. This may translate into improved
graft patency—a benefit that has been demonstrated in coronary-
stent recipients, for whom clopidogrel therapy reduces the risk of
stent thrombosis. Another potential benefit of clopidogrel in
CABG patients may be a reduction in the risk or severity of native
coronary or cerebral arterial events.
The authors concluded that “aspirin plus clopidogrel is more
effective in venous graft patency than aspirin alone.” The study
was not designed to, and could not, address the important
question of how dual antiplatelet therapy affects major adverse
cardiac and cerebrovascular events. What is striking, however, is
the absence of data relating to bleeding, which is the main
adverse effect of such therapy. It would be interesting to know
whether there was an increase in re-explorations for bleeding,
cases of pericardial effusion, transfusion requirements, chest
tube output, or nonsurgical bleeding episodes in the dual-
therapy arm.
The ideal antiplatelet therapy for optimizing graft patency and
outcomes after CABG remains uncertain, and we agree with the
authors that a larger randomized controlled trial with longer
follow-up is needed to evaluate the comparative effectiveness of
monotherapy with aspirin versus dual therapy with aspirin and a
P2Y12 receptor antagonist in patients who have undergone
CABG. Future studies ideally should incorporate pharmacogenetic
analysis, because different patients may require different antiplate-
let regimens.
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Reply
We thank Drs. Bakaeen and Chu for their comments regarding
our paper (1). In fact, we have not observed any statistical
difference in major adverse cardiac and cerebrovascular events
between the dual antiplatelet group and the aspirin-only group at
post-operative month 3, and the same is true of the post-operative
pleural effusion, transfusion requirements, or nonsurgical bleeding
groups. We did not evaluate platelet function; consequently,
individual variability in the antiplatelet therapy was not taken into
account. However, being consistent with your suggestion, we
believe that this issue should be a direction for future studies.
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